FibroGen's pamrevlumab improves survival in Phase I/II for pancreatic cancer

FibroGen Inc. (NASDAQ:FGEN) reported additional data from 37 treatment-naïve patients with locally advanced, unresectable pancreatic cancer in

Read the full 178 word article

User Sign In